Guideline for stratified screening and surveillance in patients with high risk of primary liver cancer (2020)

Abstract

The age-adjusted incidence of primary liver cancer (PLC) has been declining in China. However, PLC cases in China account for 55% globally. The disease burden is still high and the five-year survival rate has not improved significantly in the past two decades. This guideline outlines PLC screening in populations with high risk, both in the hospital and community settings. Liver cirrhosis and chronic hepatitis B are the main causes of PLC in China. For better PLC surveillance and screening in clinical practices, it is recommended that these populations be stratified into four risk levels, namely, low-, intermediate-, high-, and extremely high-risk. A lifelong surveillance is suggested for those with risks of PLC. The intervals and tools for surveillance and screening are recommended based on risk levels. Abdominal ultrasonography combined with serum alpha-fetoprotein tests (routine surveillance) is recommended every 6 months for high risk PLC. Routine surveillance every 3 months and enhanced CT/MRI examinations every 6-12 months is recommended for those with extremely high risk of PLC. The surveillance interval can be extended to one year or longer for those with low or intermediate risk because the annual incidence of low risk PLC is relatively low. The cost-effectiveness of these recommendations remains to be evaluated.

Keywords

Primary liver cancer / cirrhosis / chronic hepatitis B / screening / surveillance

References

[1] Liver Cancer Professional Committee of Chinese Anti-Cancer Association, Liver Cancer Group, Chinese Association of Liver Diseases, Pathology Committee of Chinese Anti-Cancer AssociationEvidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer (in Chinese, 2015 edition)..J Clin Exp Pathol2015;241-6

[2] Allemani C,Di Carlo V.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries..Lancet2018;391:1023-75 PMCID:PMC5879496

[3] Tsilimigras DI,Sahara K.Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification..Ann Surg Oncol2019;26:3693-700

[4] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases..Hepatology2018;68:723-50

[5] European Association for the Study of the Liver, European Association for the Study of the LiverEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[6] Korean Liver Cancer Association, National Cancer Center2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma..Gut Liver2019;13:227-99 PMCID:PMC6529163

[7] Benson AB,Abbott DE.Guidelines insights: hepatobiliary cancers, version 2.2019..J Natl Compr Canc Netw2019;17:302-10

[8] Vogel A,Chau I.Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2018;29:iv238-55

[9] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update..Hepatol Int2017;11:317-70 PMCID:PMC5491694

[10] Department of Medical Administration, National Health and Health Commission of the People’s Republic of China[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]..Zhonghua Gan Zang Bing Za Zhi2020;28:112-28

[11] Kudo M,Izumi N.JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan..Liver Cancer2014;3:458-68 PMCID:PMC4531423

[12] Kudo M.Management of hepatocellular carcinoma in Japan as a World-Leading Model..Liver Cancer2018;7:134-47 PMCID:PMC5985410

[13] Yaman ME,Senturk S.A critical appraisal of the North American Spine Society guidelines with the Appraisal of Guidelines for Research and Evaluation II instrument..Spine J2015;15:777-81

[14] Kanwal F.Surveillance for hepatocellular carcinoma: current best practice and future direction..Gastroenterology2019;157:54-64 PMCID:PMC6636644

[15] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis..Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[16] Atiq O,Yopp AC.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis..Hepatology2017;65:1196-205 PMCID:PMC5659110

[17] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma..J Hepatol2012;57:69-76 PMCID:PMC3804834

[18] Wang M,Feng X.Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center..Int J Infect Dis2017;65:15-21

[19] Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)..Zhonghua Gan Zang Bing Za Zhi2020;28:14-20

[20] Nault JC,Caruso S.Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma..Hepatology2020;71:164-82

[21] Kobayashi M,Hosaka T.Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis..Cancer2006;106:636-47

[22] Fateen W.Screening for hepatocellular carcinoma: patient selection and perspectives..J Hepatocell Carcinoma2017;4:71-9 PMCID:PMC5440035

[23] Zheng R,Zhang S.Liver cancer incidence and mortality in China: Temporal trends and projections to 2030..Chin J Cancer Res2018;30:571-9 PMCID:PMC6328503

[24] Fitzmaurice C,Abbasi N.Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study..JAMA Oncol2019;5:1749-68 PMCID:PMC6777271

[25] Prevention of Infection-related Cancer (PIRCA) Group, Specialized Commmittee of Cancer Prevention and Control, Chinese Preventive Medicine Association; Non-communicable & Chronic Disease Control and Prevention Society, Chinese Preventive Medicine Association; Heallth Communication Society, Chinese Preventive Medicine AssociationStrategies of primary prevention of liver cancer in China: expert consensus (2018)..Chin J Oncol2018;40:550-7

[26] Zeng HM,Zheng RS.Trend analysis of age of diagnosis for liver cancer in cancer registry areas of China, 2000-2014..Zhonghua Yu Fang Yi Xue Za Zhi2018;52:573-8

[27] Zhou M,Zeng X.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017..Lancet2019;394:1145-58 PMCID:PMC6891889

[28] Eslam M,George J.MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease..Gastroenterology2020;158:1999-2014.e1

[29] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[30] Chinese Society of Infectious Diseases, Chinese Medical Association., Chinese Society of Hepatology, Chinese Medical AssociationThe guidelines of prevention and treatment for chronic hepatitis B (2019 version)..Zhonghua Gan Zang Bing Za Zhi2019;27:938-61

[31] Chinese Society of Hepatology., Chinese Society of Infectious Diseases, Chinese Medical Association[Guidelines for the prevention and treatment of hepatitis C (2019 version)]..Zhonghua Gan Zang Bing Za Zhi2019;27:962-79

[32] Sharma SA,Hansen BE.Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis..J Hepatol2017;92-9

[33] Ganne-Carrié N,Bourcier V.Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis..J Hepatol2018;69:1274-83

[34] Kim BS,Kim YS.Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis..J Gastroenterol Hepatol2018;33:503-10

[35] de Martel C,Bray F,Clifford GM.Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis..Lancet Global Health2020;8:e180-90

[36] Shi Y,Wu W,Yang J.Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis..Liver Int2012;32:231-40

[37] Loomba R,Yang HI.Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma..Clin Gastroenterol Hepatol2013;11:1636-45.e1-3 PMCID:PMC4100777

[38] Fan C,Gan Y.A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China..Gut2019;68:948-9

[39] Yang H,Chan HL.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score..Lancet Oncology2011;12:568-74

[40] Tseng TC,Hsu CY.High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load..Gastroenterology2019;157:1518-1529.e3

[41] Tseng TC,Yang HC.High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load..Gastroenterology2012;142:1140-1149.e3quiz e13-4

[42] Baudi I,Tanaka Y.Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi..Int J Mol Sci2020;21:949 PMCID:PMC7037346

[43] Liu S,Gu C.Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis..J Natl Cancer Inst2009;101:1066-82 PMCID:PMC2720989

[44] Yin J,Liu S.Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma..Am J Gastroenterol2011;106:81-92

[45] Bai X,Jin Y.Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma..Carcinogenesis2011;32:63-8 PMCID:PMC3025712

[46] Yin J,Zhang H.Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma..J Gastroenterol2010;45:1063-71

[47] Lin CL.Prevention of hepatitis B virus-related hepatocellular carcinoma..Hepatoma Res2021;7:9

[48] Yip TC,Chan HL,Lui GC.Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China..Gastroenterology2020;158:215-225.e6

[49] Yin J,Pu R.Hepatitis B virus combo mutations improve the prediction and active prophylaxis of hepatocellular carcinoma: a clinic-based cohort study..Cancer Prev Res (Phila)2015;8:978-88

[50] Han Y,Liao H,Chen Y.The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis..Int Immunopharmacol2017;42:168-75

[51] Ren H.Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B..J Viral Hepat.2019;26 Suppl 1:5-31

[52] Maucort-Boulch D,Franceschi S.Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide..Int J Cancer2018;142:2471-7

[53] Yang F,Yang Y.Contribution of hepatitis B virus infection to the aggressiveness of primary liver cancer: a clinical epidemiological study in Eastern China..Front Oncol2019;9:370 PMCID:PMC6537574

[54] Turati F,Talamini R.Family history of liver cancer and hepatocellular carcinoma..Hepatology2012;55:1416-25

[55] Ma L,Wang W.Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients..Future Oncol2020;16:675-86

[56] Hassan MM,Hatten CJ.Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus..Hepatology2002;36:1206-13

[57] Shen Y,Lu L.Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study..Cancer Causes Control2020;31:321-32 PMCID:PMC7136513

[58] Galicia-Moreno M,Campos-Valdez M.Hepatocellular carcinoma and hepatitis C virus infection in Latin America: epidemiology, diagnosis and treatment..Hepatoma Res2020;6:20

[59] Heckley GA,Asamoah BO.How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature..BMC Cancer2011;11:446 PMCID:PMC3229519

[60] Berkan-Kawińska A.Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges..Curr Med Res Opin2020;36:235-43

[61] Nevola R,Giordano M.Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease..Hepatoma Res2018;4:55

[62] Alexander M,van der Lei J.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts..BMC Med2019;17:95 PMCID:PMC6526616

[63] Wang Z,Chen S.Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China..Clin Gastroenterol Hepatol2020;S1542-3565(20)30643-1

[64] Yang WS,Bray F.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies..PLoS One2011;6:e27326 PMCID:PMC3244388

[65] Pan XF,Yu C.Type 2 diabetes and risk of incident cancer in China: a prospective study among 0.5 million Chinese adults..Am J Epidemiol2018;187:1380-91 PMCID:PMC6153481

[66] Ross RK,Yu MC.Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma..Lancet1992;339:943-6

[67] Sun Z,Thorgeirsson SS.Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China..Carcinogenesis2013;34:1800-5 PMCID:PMC3731800

[68] Ng AWT,Huang MN.Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia..Sci Transl Med2017;9:eaan6446

[69] Chen CJ,Lin MH.Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection..Int J Cancer2018;143:1578-87

[70] Chiang CJ,You SL,Chen CJ.Thirty-year outcomes of the national hepatitis B immunization program in Taiwan..JAMA2013;310:974-6

[71] Thomas DL.Global Elimination of Chronic Hepatitis..N Engl J Med2019;380:2041-50

[72] Zhang H,Xi L,Wu A.Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study..World J Surg Oncol2019;17:75 PMCID:PMC6492382

[73] Dyson J,Chattopadyhay D.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team..J Hepatol2014;60:110-7

[74] Kim JH,Kang W.Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment..Hepatology2017;66:335-43

[75] Wang HM,Lu SN.Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients..Liver Int2013;33:756-61

[76] Lee HA,Kim IH.Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase..Aliment Pharmacol Ther2020;52:196-204

[77] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy..J Hepatol2016;64:800-6

[78] Yip TC,Wong VW.Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B..J Hepatol2020;72:847-54

[79] Papatheodoridis GV,Dalekos GN.Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B..J Hepatol2020;72:1088-96

[80] Li L,Chen YH.Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study..World J Gastroenterol2013;19:8373-81 PMCID:PMC3857462

[81] Raimondi S,Mondelli MU.Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis..J Hepatol2009;50:1142-54

[82] Pons M,Esteban JI.Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals..J Hepatol2020;72:472-80

[83] Younossi ZM.Non-alcoholic fatty liver disease - A global public health perspective..J Hepatol2019;70:531-44

[84] Liu X,Wu M.Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population..Liver Int2019;39:1490-503 PMCID:PMC6705127

[85] Fan R,Sun J.aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis..J Hepatol2020;73:1368-78

[86] Erkan B,Clark TJ,Lambert JR.Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC..PLoS One2019;14:e0226291 PMCID:PMC6903758

[87] Harris PS,Gray ME,McGuire BM.Hepatocellular carcinoma surveillance: An evidence-based approach..World J Gastroenterol2019;25:1550-9 PMCID:PMC6452232

[88] Kudo M,Osaki Y.B-Mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial..Liver Cancer2019;8:271-80 PMCID:PMC6738204

[89] Zhang J,Li Y.Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016..Oncotarget2017;8:75418-26 PMCID:PMC5650432

[90] Kim TH,Lee JM.Emerging role of hepatobiliary magnetic resonance contrast Media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma: emphasis on recent updates in Major Guidelines..Korean J Radiol2019;20:863-79 PMCID:PMC6536788

[91] Renzulli M,Brocchi S.New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm..Gut2018;67:1674-82

[92] Kim SY,Lim YS.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma..JAMA Oncol2017;3:456-63 PMCID:PMC5470420

[93] Zhang X,Zhang KH,He YT.Simple clinical metrics enhance AFP to effectively identify cirrhotic patients with complicating hepatocellular carcinoma at various AFP levels..Front Oncol2019;9:1478 PMCID:PMC6993280

[94] McMahon BJ,Harpster A.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study..Hepatology2000;32:842-6

[95] Wong GL,Tse YK.On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir..Hepatology2014;59:986-95

[96] Worland T,Delmenico L.Hepatocellular carcinoma screening utilising serum alpha-fetoprotein measurement and abdominal ultrasound is more effective than ultrasound alone in patients with non-viral cirrhosis..J Gastrointest Cancer2018;49:476-80

[97] Xing H,Han J.Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis..Hepatobiliary Pancreat Dis Int2018;17:487-95

[98] Ji J,Li Y.Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: A large-scale, multicentre study..PLoS One2016;11:e0153227 PMCID:PMC4829182

[99] Yi X,Bao Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis..Clin Chim Acta2013;425:212-20

[100] Best J,Heider D.The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma..Z Gastroenterol2016;54:1296-305

[101] Berhane S,Tada T.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients..Clin Gastroenterol Hepatol2016;14:875-886.e6

[102] Chen H,Li S.Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma..Cancer Manag Res2018;10:1947-58 PMCID:PMC6044429

[103] Peng C,Wang Z.Circulating microRNAs for the diagnosis of hepatocellular carcinoma..Dig Liver Dis2019;51:621-31

[104] Zhou J,Gao X.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma..J Clin Oncol2011;29:4781-8

[105] Wan JCM,Garcia-Corbacho J.Liquid biopsies come of age: towards implementation of circulating tumour DNA..Nat Rev Cancer2017;17:223-38

[106] Cai J,Zhang Z.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma..Gut2019;68:2195-205 PMCID:PMC6872444

[107] Xu RH,Krawczyk M.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma..Nat Mater2017;16:1155-61

[108] Prensner JR,Srivastava S.Systematic, evidence-based discovery of biomarkers at the NCI..Clin Exp Metastasis2012;29:645-52 PMCID:PMC3679913

[109] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis..PLoS Med2014;11:e1001624 PMCID:PMC3972088

[110] Yang B,Xu Y.Prospective study of early detection for primary liver cancer..J Cancer Res Clin Oncol1997;123:357-60

[111] Giannini EG,Erroi V,Odaldi F.Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?.World J Gastroenterol2013;19:8808-21 PMCID:PMC3870532

[112] Frenette CT,Bargellini I,Singal AG.A Practical Guideline for hepatocellular carcinoma screening in patients at risk..Mayo Clin Proc Innov Qual Outcomes2019;3:302-10 PMCID:PMC6713857

[113] Izzo F,Albino V.Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients..HPB (Oxford)2013;15:985-90 PMCID:PMC3843617

[114] Lok AS,Brown RS Jr.Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis..Hepatology2016;63:284-306

[115] Singal AG,Volk ML.Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis..Cancer Epidemiol Biomarkers Prev2012;21:793-9 PMCID:PMC5640437

[116] Papatheodoridis GV,Dalekos GN.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B..Hepatology2017;66:1444-53

[117] Jepsen P,West J,Sørensen HT.Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis..J Hepatol2020;73:1030-6

[118] Wang JH,Kee KM.Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community..Am J Gastroenterol2013;108:416-24

[119] Wu CY,Ho HJ,Lee TY.Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study..Gut2016;65:693-701

[120] Li P,Xu H.Shorten liver cancer surveillance interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma..J Clin Hepatol2017;33:1301-4

[121] Trinchet JC,Bourcier V.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities..Hepatology2011;54:1987-97

[122] Kee KM.Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan..Oncology.2011;81 Suppl 1:36-40

[123] Kuo MJ,Chen CL.Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening..World J Gastroenterol2016;22:3460-70 PMCID:PMC4806204

[124] Goldberg DS,Serper M.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis..Hepatology2017;65:864-74

[125] Zhao C,Le RH.Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue..Liver Int2018;38:503-14

[126] Singal AG,Murphy CC.Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis..Clin Gastroenterol Hepatol2020;S1542-3565(20)30912-5 PMCID:PMC7779689

[127] Singal AG,Li X,Chubak J.Hepatocellular carcinoma surveillance among patients with cirrhosis in a population-based integrated Health Care Delivery System..J Clin Gastroenterol2017;51:650-5 PMCID:PMC5436954

[128] Likhitsup A.Economic implications of hepatocellular carcinoma surveillance and treatment: A guide for clinicians..Pharmacoeconomics2020;38:5-24

[129] Goossens N,King LY.Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis..Clin Transl Gastroenterol2017;8:e101 PMCID:PMC5518949

[130] Lu WP.Hepatectomy for hepatocellular carcinoma in the era of liver transplantation..World J Gastroenterol2014;20:9237-44 PMCID:PMC4110553

[131] Yin J,Han Y.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study..J Clin Oncol2013;31:3647-55

[132] Chen L,Chang W.Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma..Eur J Cancer2012;48:1977-87

[133] Lu WP.Hepatectomy for hepatocellular carcinoma in the era of liver transplantation..World J Gastroenterol2014;20:9237-44 PMCID:PMC4110553

[134] Chen Q,Laurence AD.Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial..Gut2018;67:2006-16

[135] Saito R,Hosomura N.Prognostic factors for post-recurrent survival in hepatocellular carcinoma after curative resection..Anticancer Res2019;39:3033-8

[136] Zhou HY,Chen WD.Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis..J Gastroenterol Hepatol2015;30:977-983

[137] Yin J,Li N.Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma..Carcinogenesis2020;bgaa127

[138] Choi J,Lim YS.Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection..Hepatology2020;

[139] Finn RS,Ikeda M.Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma..N Engl J Med2020;382:1894-905

[140] He C,Hao Y.Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway..Biochem Biophys Res Commun2018;503:3093-9